Cargando…
How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections
Nowadays the most important problem in the treatment of bacterial infections is the appearance of MDR (multidrug-resistant), XDR (extensively drug-resistant) and PDR (pan drug-resistant) bacteria and the scarce prospects of producing new antibiotics. There is renewed interest in revisiting the use o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954843/ https://www.ncbi.nlm.nih.gov/pubmed/32021319 http://dx.doi.org/10.2147/IDR.S234353 |
_version_ | 1783486857767550976 |
---|---|
author | Taati Moghadam, Majid Amirmozafari, Nour Shariati, Aref Hallajzadeh, Masoumeh Mirkalantari, Shiva Khoshbayan, Amin Masjedian Jazi, Faramarz |
author_facet | Taati Moghadam, Majid Amirmozafari, Nour Shariati, Aref Hallajzadeh, Masoumeh Mirkalantari, Shiva Khoshbayan, Amin Masjedian Jazi, Faramarz |
author_sort | Taati Moghadam, Majid |
collection | PubMed |
description | Nowadays the most important problem in the treatment of bacterial infections is the appearance of MDR (multidrug-resistant), XDR (extensively drug-resistant) and PDR (pan drug-resistant) bacteria and the scarce prospects of producing new antibiotics. There is renewed interest in revisiting the use of bacteriophage to treat bacterial infections. The practice of phage therapy, the application of phages to treat bacterial infections, has been around for approximately a century. Phage therapy relies on using lytic bacteriophages and purified phage lytic proteins for treatment and lysis of bacteria at the site of infection. Current research indicates that phage therapy has the potential to be used as an alternative to antibiotic treatments. It is noteworthy that, whether phages are used on their own or combined with antibiotics, phages are still a promising agent to replace antibiotics. So, this review focuses on an understanding of challenges of MDR, XDR, and PDR bacteria and phages mechanism for treating bacterial infections and the most recent studies on potential phages, cocktails of phages, and enzymes of lytic phages in fighting these resistant bacteria. |
format | Online Article Text |
id | pubmed-6954843 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-69548432020-02-04 How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections Taati Moghadam, Majid Amirmozafari, Nour Shariati, Aref Hallajzadeh, Masoumeh Mirkalantari, Shiva Khoshbayan, Amin Masjedian Jazi, Faramarz Infect Drug Resist Review Nowadays the most important problem in the treatment of bacterial infections is the appearance of MDR (multidrug-resistant), XDR (extensively drug-resistant) and PDR (pan drug-resistant) bacteria and the scarce prospects of producing new antibiotics. There is renewed interest in revisiting the use of bacteriophage to treat bacterial infections. The practice of phage therapy, the application of phages to treat bacterial infections, has been around for approximately a century. Phage therapy relies on using lytic bacteriophages and purified phage lytic proteins for treatment and lysis of bacteria at the site of infection. Current research indicates that phage therapy has the potential to be used as an alternative to antibiotic treatments. It is noteworthy that, whether phages are used on their own or combined with antibiotics, phages are still a promising agent to replace antibiotics. So, this review focuses on an understanding of challenges of MDR, XDR, and PDR bacteria and phages mechanism for treating bacterial infections and the most recent studies on potential phages, cocktails of phages, and enzymes of lytic phages in fighting these resistant bacteria. Dove 2020-01-07 /pmc/articles/PMC6954843/ /pubmed/32021319 http://dx.doi.org/10.2147/IDR.S234353 Text en © 2020 Taati Moghadam et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Taati Moghadam, Majid Amirmozafari, Nour Shariati, Aref Hallajzadeh, Masoumeh Mirkalantari, Shiva Khoshbayan, Amin Masjedian Jazi, Faramarz How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections |
title | How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections |
title_full | How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections |
title_fullStr | How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections |
title_full_unstemmed | How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections |
title_short | How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections |
title_sort | how phages overcome the challenges of drug resistant bacteria in clinical infections |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954843/ https://www.ncbi.nlm.nih.gov/pubmed/32021319 http://dx.doi.org/10.2147/IDR.S234353 |
work_keys_str_mv | AT taatimoghadammajid howphagesovercomethechallengesofdrugresistantbacteriainclinicalinfections AT amirmozafarinour howphagesovercomethechallengesofdrugresistantbacteriainclinicalinfections AT shariatiaref howphagesovercomethechallengesofdrugresistantbacteriainclinicalinfections AT hallajzadehmasoumeh howphagesovercomethechallengesofdrugresistantbacteriainclinicalinfections AT mirkalantarishiva howphagesovercomethechallengesofdrugresistantbacteriainclinicalinfections AT khoshbayanamin howphagesovercomethechallengesofdrugresistantbacteriainclinicalinfections AT masjedianjazifaramarz howphagesovercomethechallengesofdrugresistantbacteriainclinicalinfections |